Research programme: adeno-associated virus gene therapy - Kings College London/Pfizer

Drug Profile

Research programme: adeno-associated virus gene therapy - Kings College London/Pfizer

Alternative Names: AAV gene therapy - Kings College London/Pfizer

Latest Information Update: 06 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kings College London
  • Developer Alcyone Lifesciences; Kings College London; Pfizer
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Inborn genetic disorders
  • Research Neurodegenerative disorders

Most Recent Events

  • 30 Jun 2017 Pfizer and Alcyone Lifesciences enter into an agreement for the development of adeno-associated virus gene therapy for Neurodegenerative disorders
  • 30 Jun 2017 Early research in Neurodegenerative disorders in USA (Intrathecal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top